Cornea

Adam Muzychuk, MD, BSc, FRCSC, discusses his ASCRS 2024 presentation on toric lens use for patients with low astigmatism

Researchers conducted a retrospective chart review spanning from January 2015 to January 2021 to compare the incidence rates of infectious keratitis before and during the pandemic among PRK patients.

Greg Kunst, CEO of Aurion Biotech, discusses AURN001, a novel cell therapy targeting corneal endothelial disease

At ASCRS2024, George O. Waring IV, MD, FACS, provides an overview of his presentation highlighting outcomes for LASIK performed using an updated laser ablation algorithm

Ula Jurkunas, MD, sat down to discuss her presentation on the management of anterior corneal disease at this year's ASCRS meeting held in Boston, Massachusetts.

The company announced it will share clinical data at Eyecelerator and the American Society of Cataract and Refractive Surgery 2024 Annual Meeting in Boston.

The 1-time, intracameral injection is a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Alice Epitropoulos, MD, discusses the importance of considering ocular surface health in cataract surgery patients.

Laser blended vision is a proven modality for presbyopia treatment, but its principles can be reproduced with EDOF IOLs

Alexander Movshovich, MD, PhD, a specialist in keratopigmentation, sat down to talk about the controversy surrounding the procedure after it went viral on social media.

Clara Chan, MD, shares surgical pearls for neurotrophic keratopathy and explores new pathways through neurotisation

Penetrating keratoplasty remains a popular choice for certain patients

Early keratoconus screening advocated

Shifting the treatment paradigm can lead to less pain and inflammation.

The funding has been awarded to BIENCO, which is working to cure one of the most common causes of blindness in the world by developing cost effective, individually tailored, superior corneas.

The company, headquarted in New York and London, named OK-101 as the first IND clearance granted by the FDA for a drug to begin clinical studies specifically to treat NCP

OK-101 is the first IND clearance granted by the FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain.

Postoperative outcomes of the tissues obtained from these donors were satisfactory

Patient selection is important.

Researchers found the administration of the neuropeptide α–melanocyte–stimulating hormone promotes corneal healing and restores normal eye function to an otherwise degenerating and diseased cornea by providing protection against cell death and promoting cell regeneration.

Physicians from the Harvard Medical School and the Kresge Eye Institute at Wayne State University in Detroit recently published details from the case.

Why “acceleration” is the industry keyword for 2024

Restoration and regeneration represent a new paradigm